HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting-Reference-Cited by-同舟云学术

HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent In Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting

Published:2020-12-08 Issue:1 Volume:40 Page:17-23
ISSN:0277-1691
Container-title:International Journal of Gynecological Pathology
language:en
Short-container-title:

Author:

Buza Natalia

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology,Pathology and Forensic Medicine

Reference41 articles.

1. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers;Hamilton;Br J Cancer,2006

2. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial;de Boer;Lancet Oncol,2019

3. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study;Homesley;Gynecol Oncol,2009

4. Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy;Tortorella;Gynecol Oncol,2018

5. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer;Menderes;Discov Med,2016

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic indications for antibody-drug conjugates estimated from HER2 and p53 expressions in endometrial carcinoma;Human Pathology;2024-10

2. Comparison of antigenicity between frozen section vs non−frozen section tissue blocks: An immunohistochemical study of antibodies commonly used in gynecologic pathology;American Journal of Clinical Pathology;2024-08-07

3. Image analysis for bright-field HER2 in situ hybridization: validation for clinical use;Virchows Archiv;2024-08-07

4. Human epidermal growth factor 2 (HER2) amplification in uterine serous carcinoma: an analysis of prognosis and immune microenvironment;Virchows Archiv;2024-07-29

5. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations;International Journal of Gynecological Pathology;2024-06-10